Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
  • A61P31/22—Antivirals for DNA viruses for herpes viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/14—Blood; Artificial blood
  • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
  • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/14—Blood; Artificial blood
  • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/10—Cellular immunotherapy characterised by the cell type used
  • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
  • A61K40/46—Viral antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
  • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Definitions

• EBV-LPD Epstein-Barr Virus-associated lymphoproliferative disorder
• methods of treating an EBV-LPD comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T cells.
• Epstein-Barr Virus-associated lymphoproliferative disorders are a significant cause of morbidity and mortality for solid organ transplant recipients, hematopoietic stem cell transplant recipients, and other immunocompromised patients.
• Different therapies have been developed to treat EB V-LPDs, such as chemotherapy, combination chemotherapy, radiation therapy, therapy with rituximab (an anti-CD20 monoclonal antibody), and cellular
• EPOCH Dose- Adjusted EPOCH, which is a therapy regimen with etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin.
• regimens include intrathecal rituximab, radiation or high dose methotrexate alone for CNS only disease, or in combination for systemic and CNS disease.
• EBV-LPD that is resistant to a previous therapy is usually more aggressive. This is especially true when the previous therapy is chemotherapy or radiation therapy, which often leads to or selects for mutated tumor cells, resulting in a much more aggressive disease.
• First-line therapies are usually selected based on their desirable combination of safety and efficacy, while later lines of therapy are usually considered less desirable in terms of their safety and/or efficacy profiles.
• the present invention relates to methods of treating an EBV-LPD (Epstein-Barr
• Virus-associated lymphoproliferative disorder in a human patient who has failed combination chemotherapy to treat the EBV-LPD and/or radiation therapy to treat the EBV-LPD.
• kits for treating an EBV-LPD in a human patient comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T cells; wherein the human patient has failed a combination chemotherapy to treat the EBV-LPD, and wherein the population of allogeneic T cells is restricted by an human leukocyte antigen (HLA) allele shared with cells of the EBV-LPD.
• HLA human leukocyte antigen
• the population of allogeneic T cells is human.
• the EBV-LPD is resistant to the combination chemotherapy to treat the EBV-LPD.
• the human patient has been taken off the combination chemotherapy due to intolerance of the combination chemotherapy.
• the combination chemotherapy that the human patient has failed comprises therapy with cyclophosphamide and prednisone. In a further specific embodiment, the combination chemotherapy that the human patient has failed comprises a low- dose cyclophosphamide and prednisone regimen. In another specific embodiment, the combination chemotherapy that the human patient has failed comprises therapy with
• the combination chemotherapy that the human patient has failed comprises a low-dose
• the human patient also has failed multiple different combination chemotherapies to treat the EBV-LPD.
• the EBV-LPD is resistant to the multiple different combination chemotherapies to treat the EBV-LPD.
• the human patient has been taken off the multiple different combination chemotherapies due to intolerance of the multiple different combination
• At least one of the multiple different combination chemotherapies that the human patient has failed comprises therapy with cyclophosphamide and prednisone. In a further specific embodiment, at least one of the multiple different combination chemotherapies that the human patient has failed comprises a low-dose cyclophosphamide and prednisone regimen. In another specific embodiment, at least one of the multiple different combination chemotherapies that the human patient has failed comprises therapy with cyclophosphamide and methylprednisolone. In another further specific embodiment, at least one of the multiple different combination chemotherapies that the human patient has failed comprises a low-dose cyclophosphamide and methylprednisolone regimen.
• the human patient who has failed a combination chemotherapy to treat the EBV-LPD also has failed a radiation therapy to treat the EBV-LPD.
• the EBV-LPD is resistant to the radiation therapy to treat the EBV-LPD.
• the human patient has been taken off the radiation therapy due to intolerance of the radiation therapy.
• kits for treating an EBV-LPD in a human patient comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T cells; wherein the human patient has failed a radiation therapy to treat the EBV-LPD, and wherein the population of allogeneic T cells is restricted by an HLA allele shared with cells of the EBV-LPD.
• the EBV-LPD is resistant to the radiation therapy to treat the EBV-LPD.
• the human patient has been taken off the radiation therapy due to intolerance of the radiation therapy.
• the human patient in addition to failing a combination chemotherapy (or multiple different combination chemotherapies) and/or a radiation therapy as described above, the human patient also has failed a therapy with an anti-CD20 monoclonal antibody to treat the EBV-LPD.
• the EBV-LPD is resistant to the therapy with the anti-CD20 monoclonal antibody to treat the EBV-LPD.
• the human patient has been taken off the therapy with the anti-CD20 monoclonal antibody due to intolerance of the therapy with the anti-CD20 monoclonal antibody.
• the anti-CD20 monoclonal antibody is rituximab.
• the population of allogeneic T cells comprising EBV-specific T cells shares at least 2 out of 8 HLA alleles with cells of the EBV-LPD.
• the 8 HLA alleles are two HLA-A alleles, two HLA-B alleles, two HLA-C alleles, and two HLA-DR alleles.
• the methods of treating an EBV-LPD as described herein further comprise prior to the administering step a step of ascertaining at least one HLA allele of cells of the EBV-LPD by high-resolution typing.
• the methods of treating an EBV-LPD further comprise prior to the administering step a step of generating the population of allogeneic T cells in vitro.
• the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells to one or more EBV antigens.
• the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells using EBV-transformed B cells.
• the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells using EBV strain B95.8-transformed B cells.
• the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells using dendritic cells, cytokine-activated monocytes, or peripheral blood mononuclear cells.
• the step of sensitizing allogeneic T cells using dendritic cells, cytokine-activated monocytes, or peripheral blood mononuclear cells comprises loading the dendritic cells, the cytokine-activated monocytes, or the peripheral blood mononuclear cells with at least one immunogenic peptide derived from one or more EBV antigens.
• the step of sensitizing allogeneic T cells using dendritic cells, cytokine-activated monocytes, or peripheral blood mononuclear cells comprises loading the dendritic cells, the cytokine-activated monocytes, or the peripheral blood mononuclear cells with a pool of overlapping peptides derived from one or more EBV antigens.
• the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells using artificial antigen-presenting cells
• the step of sensitizing allogeneic T cells using AAPCs comprises loading the AAPCs with at least one immunogenic peptide derived from one or more EBV antigens. In specific embodiments, the step of sensitizing allogeneic T cells using AAPCs comprises loading the AAPCs with a pool of overlapping peptides derived from one or more EBV antigens. In specific embodiments, the step of sensitizing allogeneic T cells using AAPCs comprises engineering the AAPCs to express at least one immunogenic EBV peptide or protein in the AAPCs.
• the step of generating the population of allogeneic T cells in vitro further comprises, after sensitizing, cryopreserving the allogeneic T cells.
• the methods of treating an EBV-LPD as described herein further comprise, before the administering step, steps of thawing cryopreserved EBV- antigen sensitized allogeneic T cells, and expanding the allogeneic T cells in vitro, to produce the population of allogeneic T cells.
• the methods of treating an EBV-LPD as described herein further comprise, before the administering step, a step of thawing a cryopreserved form of the population of allogeneic T cells.
• the population of allogeneic T cells is derived from a T cell line.
• the methods of treating an EBV-LPD as described herein further comprise, before the administering step, a step of selecting the T cell line from a bank of a plurality of cryopreserved T cell lines.
• the methods of treating an EBV-LPD as described herein further comprise, before the administering step, a step of thawing a cryopreserved form of the T cell line.
• the methods of treating an EBV-LPD as described herein further comprises, before the administering step, a step of expanding the T cell line in vitro.
• the EBV-specific T cells administered in accordance with the methods described herein recognizes an EBV antigen that is EBNA1, EBNA2,
• EBNA3A EBNA3A
• EBNA3B EBNA3C
• LMP1 LMP2.
• the administering is by infusion of the population of allogeneic T cells. In some embodiments, the infusion is bolus intravenous infusion. In certain embodiments, the administering comprises administering at least about 1 x 10 5 T cells of the population of allogeneic T cells per kg per dose per week to the human patient. In some embodiments, the administering comprises administering about 1 x 10 6 to about 2 x 10 6 T cells of the population of allogeneic T cells per kg per dose per week to the human patient. In a specific embodiment, the administering comprises administering about 1 x 10 6 T cells of the population of allogeneic T cells per kg per dose per week to the human patient. In another specific embodiment, the administering comprises administering about 2 x 10 6 T cells of the population of allogeneic T cells per kg per dose per week to the human patient.
• the methods of treating an EBV-LPD as described herein comprise administering at least 2 doses of the population of allogeneic T cells to the human patient. In specific embodiments, the methods of treating an EBV-LPD as described herein comprise administering 2, 3, 4, 5, or 6 doses of the population of allogeneic T cells to the human patient.
• the methods of treating an EBV-LPD as described herein comprise administering a first cycle of one dose per week of the population of allogeneic T cells for 3 consecutive weeks followed by a washout period during which no dose of the population of allogeneic T cells is administered, followed by a second cycle of the one dose per week of the population of allogeneic T cells for 3 consecutive weeks.
• the methods of treating an EBV-LPD as described herein comprise administering two, three, four, five, or six cycles of one dose per week of the population of allogeneic T cells for 3 consecutive weeks, each cycle separated by a washout period during which no dose of the population of allogeneic T cells is administered.
• the washout period is about three weeks.
• the methods of treating an EBV-LPD further comprise, after administering to the human patient the population of allogeneic T cells, administering to the human patient a second population of allogeneic T cells comprising EBV-specific T cells;
• the methods of treating an EBV-LPD comprise administering a first cycle of one dose per week of the population of allogeneic T cells for 3 consecutive weeks followed by a washout period during which no dose of the population of allogeneic T cells is administered, followed by a second cycle of one dose per week of the second population of allogeneic T cells for 3 consecutive weeks.
• the washout period is about three weeks.
• the human patient has no response, an incomplete response, or a suboptimal response after administering the population of allogeneic T cells and prior to administering the second population of allogeneic T cells.
• the human patient can be anyone who has an EBV-LPD and who has failed combination chemotherapy to treat the EBV-LPD (and in some embodiments, also has failed therapy with an anti-CD20 monoclonal antibody) and/or radiation therapy (and in some embodiments, also has failed therapy with an anti-CD20 monoclonal antibody).
• the EBV-LPD is an EBV-positive lymphoma.
• the EBV-LPD treated in accordance with a method described herein is present in the central nervous system of the human patient.
• the EBV- LPD treated in accordance with a method described herein is present in the brain of the human patient.
• the human patient has been the recipient of a solid organ transplant from a transplant donor.
• the human patient has been the recipient of multiple organ transplants (for example, heart and lung transplants, or kidney and pancreas transplants).
• the solid organ transplant can be, but is not limited to, a kidney transplant, a liver transplant, a heart transplant, an intestinal transplant, a pancreas transplant, a lung transplant, or a combination thereof.
• the solid organ transplant is a kidney transplant.
• the solid organ transplant is a liver transplant.
• the human patient has been the recipient of a hematopoietic stem cell transplant (HSCT) from a transplant donor.
• the HSCT can be a bone marrow transplant, a peripheral blood stem cell transplant, or a cord blood transplant.
• the population of allogeneic T cells is derived from a donor other than the transplant donor.
• the present invention relates to methods of treating an EBV-LPD (Epstein-Barr
• Virus-associated lymphoproliferative disorder in a human patient who has failed combination chemotherapy to treat the EBV-LPD and/or radiation therapy to treat the EBV-LPD.
• This invention provides a T cell therapy method that is effective in treating EBV-LPD that is resistant to combination chemotherapy or to radiation therapy, and thus finds use as a later-line therapy with low toxicity.
• kits for treating an EBV-LPD in a human patient comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T cells; wherein the human patient has failed a combination chemotherapy to treat the EBV-LPD, and wherein the population of allogeneic T cells is restricted by an human leukocyte antigen (HLA) allele shared with cells of the EBV-LPD.
• HLA human leukocyte antigen
• the EBV-LPD is resistant to the combination chemotherapy to treat the EBV-LPD.
• the human patient has been taken off the combination chemotherapy due to intolerance of the combination chemotherapy.
• the human patient also has failed multiple different combination chemotherapies to treat the EBV-LPD.
• the EBV-LPD is resistant to the multiple different combination chemotherapies to treat the EBV-LPD.
• the human patient has been taken off the multiple different combination chemotherapies due to intolerance of the multiple different combination chemotherapies.
• the human patient also has failed a radiation therapy to treat the EBV-LPD.
• the EBV-LPD is resistant to the radiation therapy to treat the EBV-LPD.
• the human patient has been taken off the radiation therapy due to intolerance of the radiation therapy.
• kits for treating an EBV-LPD in a human patient comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T cells; wherein the human patient has failed a radiation therapy to treat the EBV-LPD, and wherein the population of allogeneic T cells is restricted by an HLA allele shared with cells of the EBV-LPD.
• the EBV-LPD is resistant to the radiation therapy to treat the EBV-LPD.
• the human patient has been taken off the radiation therapy due to intolerance of the radiation therapy.
• the human patient in addition to failing a combination chemotherapy (or multiple different combination chemotherapies) and/or a radiation therapy as described above, the human patient also has failed a therapy with an anti-CD20 monoclonal antibody (for example, rituximab) to treat the EBV- LPD.
• an anti-CD20 monoclonal antibody for example, rituximab
• the EBV-LPD is resistant to the therapy with the anti-CD20 monoclonal antibody to treat the EBV-LPD.
• the human patient has been taken off the therapy with the anti-CD20 monoclonal antibody due to intolerance of the therapy with the anti-CD20 monoclonal antibody.
• a human patient is considered to have failed a therapy (e.g., combination chemotherapy, radiation therapy, and/or therapy with anti-CD20 monoclonal antibody) of EBV- LPD if the EBV-LPD is resistant to the therapy and/or if the human patient has been taken off the therapy due to intolerance of the therapy (for example, due to toxicity of the therapy in view of the patient's age or condition).
• An EBV-LPD is considered resistant to a therapy (e.g., combination chemotherapy, radiation therapy, or therapy with anti-CD20 monoclonal antibody), if the EBV-LPD has no response, or has an incomplete response (a response that is less than a complete remission), or progresses, or relapses after the therapy.
• a complete remission is a complete resolution of all clinical and radiologic evidence of the disease, optionally confirmed by biopsy of affected tissues, lasting for at least three weeks following completion of the therapy.
• Combination chemotherapy involves the therapeutic use over the same treatment period of two or more different chemotherapeutic agents to treat cancer.
• a chemotherapeutic agent is an anti-cancer cytotoxic chemical drug, generally a small molecule, synthetic organic compound, and is distinct from other types of anti-cancer agents such as biopolymers and cells.
• chemotherapeutic agents are not nucleic acids, proteins (for example, antibodies), or immune cells (for example, T cells).
• Combination chemotherapy is often attempted in order to minimize potential resistance of the cancer (e.g., EBV-LPD) to the therapy.
• a combination chemotherapy-resistant EBV- LPD is usually considered harder to treat than a single agent-resistant EBV-LPD.
• the present invention provides for treatment of a human patient with EBV-LPD who has failed a combination chemotherapy to treat the EBV-LPD.
• the combination
• chemotherapeutic agents include, but are not limited to (the combinations being of the chemotherapeutic agents in parentheses): 7+3 (7 days of cytarabine plus 3 days of an anthracycline antibiotic, either daunorubicin or idarubicin), ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), BACOD (bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone), BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone), Dose-Escalated BEACOPP, CBV (cyclophosphamide, carmustine, etoposide), COP (cyclophos
• VD-PACE bortezomib, dexamethasone, platinum agent, doxorubicin, cyclophosphamide, etoposide
• VTD-PACE bortezomib, thalidomide, dexamethasone, platinum agent, doxorubicin, cyclophosphamide, etoposide
• the combination chemotherapy that the human patient has failed is therapy with cyclophosphamide and prednisone.
• the combination chemotherapy that the human patient has failed is a low-dose cyclophosphamide and prednisone regimen.
• a low-dose cyclophosphamide and prednisone regimen is a regimen where less than about 900 mg/m 2 per dose per day of intravenous cyclophosphamide is administered for less than 8 doses, and less than 2 mg/kg per dose, given twice per day, of oral prednisone is administered.
• the combination chemotherapy is the low- dose cyclophosphamide and prednisone regimen described in Gross et al., 2012, Am J Transplant 12:3069-3075, as follows: a total of six cycles of therapy is given, and the cycles are given every 3 weeks; 600 mg/m 2 intravenous cyclophosphamide is given on day 1 of each cycle, and 1 mg/kg oral prednisone is given twice per day on days 1-5 of each cycle.
• the combination chemotherapy that the human patient has failed is therapy with cyclophosphamide and methylprednisolone.
• the combination chemotherapy that the human patient has failed is a low-dose cyclophosphamide and methylprednisolone regimen.
• the combination chemotherapy is the low-dose cyclophosphamide and methylprednisolone regimen is as described in Gross et al., 2012, Am J Transplant 12:3069-3075, as follows: a total of six cycles of therapy is given, and the cycles are given every 3 weeks; 600 mg/m 2 intravenous cyclophosphamide is given on day 1 of each cycle, and 0.8 mg/kg intravenous methylprednisolone is given every 12-hr on days 1-5 of each cycle.
• the combination chemotherapy that the human patient has failed is therapy with cyclophosphamide, prednisone, and methylprednisolone.
• the combination chemotherapy that the human patient has failed is therapy with gemcitabine and vinorelbine.
• the combination chemotherapy that the human patient has failed is therapy with methotrexate and temozolomide.
• the combination chemotherapy that the human patient has failed is therapy with methotrexate, temozolomide and cytarabine.
• the combination chemotherapy that the human patient has failed is therapy with prednisone and
• the combination chemotherapy that the human patient has failed is therapy with vincristine and cyclophosphamide.
• the combination chemotherapy that the human patient has failed is therapy with doxorubicin, vincristine, prednisone, and methotrexate.
• the combination chemotherapy that the human patient has failed is therapy with doxorubicin, vincristine, prednisone, and methotrexate.
• the combination chemotherapy that the human patient has failed is therapy with doxorubicin, vincristine, prednisone, and methotrexate.
• the combination chemotherapy that the human patient has failed is therapy with vinblastine, lomustine, and cytarabine.
• the combination chemotherapy that the human patient has failed is COP.
• the combination chemotherapy that the human patient has failed is BEACOPP.
• the combination chemotherapy that the human patient has failed is CHOP.
• the combination chemotherapy that the human patient has failed is therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, cytarabine, methotrexate, and dexamethasone.
• the combination chemotherapy that the human patient has failed is IV AC.
• the combination chemotherapy that the human patient has failed is ESHAP.
• the combination chemotherapy that the human patient has failed is therapy with melphalan and dexamethasone.
• the combination chemotherapy that the human patient has failed is ProMACE-CytaBOM.
• the combination chemotherapy that the human patient has failed is CHOP.
• the combination chemotherapy that the human patient has failed is DA-EPOCH.
• the combination chemotherapy that the human patient has failed comprises any of the combinations of chemotherapeutic agents or chemotherapeutic regimens described above. In a specific embodiment, the combination chemotherapy that the human patient has failed consists essentially of any of the combinations of chemotherapeutic agents or chemotherapeutic regimens described above.
• At least one of the multiple different combination chemotherapies is any of the combinations of chemotherapeutic agents or chemotherapeutic regimens described above.
• at least one of the multiple different combination chemotherapies comprises any of the combinations of chemotherapeutic agents or chemotherapeutic regimens described above.
• At least one of the multiple different combination chemotherapies consists essentially of any of the combinations of chemotherapeutic agents or chemotherapeutic regimens described above.
• Radiation therapies use high-energy radiation to kill cancer cells by damaging their DNA.
• the radiation therapy that the human patient has failed can be any known in the art for treatment of a LPD.
• Exemplary radiation therapies include, but are not limited to: conventional external beam radiation therapy, stereotactic radiation therapy, intensity -modulated radiation therapy, volumetric modulated arc therapy, particle therapy, auger therapy, brachytherapy, and radioisotope therapy.
• the human patient in addition to failing therapy with any of the combination chemotherapies and/or radiation therapies described above, the human patient also has failed therapy with an anti-CD20 monoclonal antibody (alone or in combination with other therapies for the EBV-LPD).
• the anti- CD20 monoclonal antibody can be any known in the art.
• the anti- CD20 monoclonal antibody is a chimeric antibody or a humanized antibody.
• the anti-CD20 monoclonal antibody is a monovalent antibody or multivalent (e.g., bivalent) antibody.
• the anti-CD20 monoclonal antibody is a
• the anti-CD20 monoclonal antibody is conjugated with a cytotoxic agent; alternatively, the anti- CD20 monoclonal antibody can be unconjugated.
• exemplary anti-CD20 monoclonal antibodies include, but are not limited to: rituximab, obinutuzumab, ocrelizumab ofatumumab,
• the anti-CD20 monoclonal antibody is rituximab.
• the human patient has failed R- CEOP (a therapy regimen with cyclophosphamide, etoposide, vincristine, prednisone, and rituximab).
• R-GEMOX a therapy regimen with gemcitabine, oxaliplatin, and rituximab.
• R-COP a therapy regimen with cyclophosphamide, vincristine,
• the human patient has failed R-CHOP (a therapy regimen with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab).
• R-CHOP a therapy regimen with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab.
• the human patient has failed a therapy with rituximab, cyclophosphamide and prednisone.
• the human patient has failed a therapy with rituximab, cyclophosphamide and methylprednisolone.
• the human patient has failed a treatment regimen described in Gross et al., 2012, Am J
• Transplant 12:3069-3075 as follows: a total of six cycles of therapy is given, and the cycles are given every 3 weeks; 600 mg/m 2 intravenous cyclophosphamide is given on day 1 of each cycle for six cycles, 1 mg/kg oral prednisone is given twice a day (or 0.8 mg/kg intravenous methylprednisolone is given every 12-hr) on days 1-5 of each cycle for six cycles, and 375 mg/m 2 intravenous rituximab is given on days 1, 8, and 15 of each cycle for the first two cycles.
• the combination chemotherapy and the therapy with the anti- CD20 monoclonal antibody can be combined in a single therapy regimen, or can be in separate therapy regimens administered over different time periods to the human patient.
• a population of allogeneic T cells comprising EBV- specific T cells is administered to the human patient.
• the population of allogeneic T cells that is administered to the human patient is restricted by an HLA allele shared with cells of the EBV- LPD.
• this HLA allele restriction is ensured by ascertaining the HLA assignment of cells of the EBV-LPD, and selecting a population of allogeneic T cells comprising EBV-specific T cells (or a T cell line from which to derive the population of allogeneic T cells) restricted by an HLA allele of such cells.
• this HLA allele restriction is ensured by ascertaining the HLA assignment of the human patient (e.g., by using non-LPD cells or tissue from the human patient), and selecting a population of allogeneic T cells comprising EBV-specific T cells (or a T cell line from which to derive the population of allogeneic T cells) restricted by an HLA allele of the human patient.
• this HLA allele restriction is ensured by determining the origin of the EBV-LPD (whether transplant donor or recipient (the human patient)), ascertaining the HLA assignment of the origin of the EBV- LPD (transplant donor or the human patient, as the case may be), and selecting a population of allogeneic T cells comprising EBV-specific T cells (or a T cell line from which to derive the population of allogeneic T cells) restricted by an HLA allele of the origin of the EBV-LPD.
• this HLA allele restriction is ensured by ascertaining the HLA assignment of both the human patient and the transplant donor, and selecting a population of allogeneic T cells comprising EBV-specific T cells (or a T cell line from which to derive the population of allogeneic T cells) restricted by an HLA allele shared by both the human patient and the transplant donor.
• the origin of the EBV-LPD can be determined by any method known in the art, for example by analyzing variable tandem repeats (VTRs), a method that uses unique DNA signature of small DNA sequences of different people to distinguish between the recipient and the donor of a transplant; or by looking for the presence or absence of chromosome Y if the donor and the recipient of a transplant are of different sexes, done by cytogenetics or by FISH (fluorescence in situ hybridization).
• VTRs variable tandem repeats
• FISH fluorescence in situ hybridization
• HLA-A, HLA-B, HLA-C, and HLA-DR are typed.
• 4 HLA loci preferably HLA-A, HLA-B, HLA-C, and HLA- DR
• 6 HLA loci are typed.
• 8 HLA loci are typed.
• the population of allogeneic T cells comprising EBV-specific T cells shares at least 2 out of 8 HLA alleles (for example, two HLA-A alleles, two HLA-B alleles, two HLA-C alleles, and two HLA-DR alleles) with cells of the EBV-LPD.
• this sharing is ensured by ascertaining the HLA assignment of cells of the EBV-LPD, and selecting a population of allogeneic T cells comprising EBV-specific T cells (or a T cell line from which to derive the population of allogeneic T cells) that shares at least 2 out of 8 HLA alleles with such cells.
• this sharing is ensured by ascertaining the HLA assignment of the human patient (e.g., by using non-LPD cells or tissue from the human patient), and selecting a population of allogeneic T cells comprising EBV-specific T cells (or a T cell line from which to derive the population of allogeneic T cells) that shares at least 2 out of 8 HLA alleles with the human patient.
• this sharing is ensured by determining the origin of the EBV-LPD (whether transplant donor or recipient (the human patient)), ascertaining the HLA assignment of the origin of the EBV-LPD (transplant donor or the human patient, as the case may be), and selecting a population of allogeneic T cells comprising EBV-specific T cells (or a T cell line from which to derive the population of allogeneic T cells) that shares at least 2 out of 8 HLA alleles with the origin of the EBV-LPD.
• the origin of the EBV-LPD is not possible in such embodiments, this is ensured by ascertaining the HLA assignment of both the human patient and the transplant donor, and selecting a population of allogeneic T cells comprising EBV-specific T cells (or a T cell line from which to derive the population of allogeneic T cells) that shares at least 2 out of 8 HLA alleles with both the human patient and the transplant donor.
• the HLA assignment i.e., the HLA loci type
• Non-limiting exemplary methods for ascertaining the HLA assignment can be found in ASHI Laboratory Manual, Edition 4.2 (2003), American Society for Histocompatibility and Immunogenetics; ASHI Laboratory Manual, Supplements 1 (2006) and 2 (2007), American Society for Histocompatibility and Immunogenetics; Hurley, "DNA-based typing of HLA for transplantation.” in Leffell et al., eds., 1997, Handbook of Human
• high-resolution typing is preferable for HLA typing.
• the high- resolution typing can be performed by any method known in the art, for example, as described in ASHI Laboratory Manual, Edition 4.2 (2003), American Society for Histocompatibility and Immunogenetics; ASHI Laboratory Manual, Supplements 1 (2006) and 2 (2007), American Society for Histocompatibility and Immunogenetics; Flomenberg et al., Blood, 104: 1923-1930; Kogler et al., 2005, Bone Marrow Transplant, 36: 1033-1041; Lee et al., 2007, Blood 110:4576- 4583; Erlich, 2012, Tissue Antigens, 80: 1-11; Lank et al., 2012, BMC Genomics 13 :378; or Gabriel et al., 2014, Tissue Antigens, 83 :65-75.
• the methods of treating an EBV-LPD as described herein further comprise prior to the administering step a step of ascertaining at least one HLA
• the HLA allele by which the population of allogeneic T cells is restricted can be determined by any method known in the art, for example, as described in Trivedi et al., 2005, Blood 105:2793-2801; Barker et al., 2010, Blood 116:5045-5049; Hasan et al., 2009, J Immunol, 183 :2837-2850; or Doubrovina et al., 2012, Blood 120: 1633-1646.
• the HLA allele by which the population of allogeneic T cells is restricted and is shared with cells of the EBV-LPD is defined by high-resolution typing.
• the HLA alleles that are shared between the population of allogeneic T cells and cells of the EBV-LPD are defined by high-resolution typing.
• both the HLA allele by which the population of allogeneic T cells is restricted and is shared with cells of the EBV-LPD, and the HLA alleles that are shared between the population of allogeneic T cells and cells of the EBV-LPD are defined by high-resolution typing.
• the population of allogeneic T cells comprising EBV-specific T cells that is administered to the human patient can be generated by a method known in the art, or can be selected from a preexisting bank (collection) of cryopreserved T cell lines (each T cell line comprising EBV-specific T cells) generated by a method known in the art, and thawed and preferably expanded prior to administration.
• a preexisting bank selection
• cryopreserved T cell lines each T cell line comprising EBV-specific T cells
• unique identifier for each T cell line in the bank is associated with information as to which HLA allele(s) the respective T cell line is restricted, and optionally also information as to the HLA assignment of the respective T cell line.
• the population of allogeneic T cells and the T cell lines in the bank are preferably obtained or generated by methods described below.
• the methods of treating an EBV-LPD further comprise prior to the administering step a step of obtaining the population of allogeneic T cells.
• the step of obtaining the population of allogeneic T cells comprises fluorescence activated cell sorting for EBV-positive T cells from a population of blood cells.
• the population of blood cells are peripheral blood mononuclear cells (PBMCs) isolated from a blood sample(s) obtained from a human donor.
• PBMCs peripheral blood mononuclear cells
• the fluorescence activated cell sorting can be performed by any method known in the art, which normally involves staining the population of blood cells with an antibody that recognizes at least one EBV antigen before the sorting step.
• the step of obtaining the population of allogeneic T cells comprises generating the population of allogeneic T cells in vitro.
• the population of allogeneic T cells can be generated in vitro by any method known in the art. Non-limiting exemplary methods of generating the population of allogeneic T cells can be found in Koehne et al., 2000, Blood 96: 109-117; Koehne, et al., 2002, Blood 99: 1730-1740; O'Reilly et al., 2007, Immunol Res 38:237-250; Barker et al., 2010, Blood 116:5045-5049; O' Reilly et al., 2011, Best Practice & Research Clinical Haematology 24:381-391; and Doubrovina et al., 2012, Blood 119:2644- 2656.
• the step of generating the population of allogeneic T cells in vitro comprises sensitizing (i.e., stimulating) allogeneic T cells to one or more EBV antigens so as to produce EBV-specific T cells.
• the allogeneic T cells that are used for generating the population of allogeneic T cells in vitro can be isolated from the donor of the allogeneic T cells by any method known in the art, for example, as described in Koehne, et al., 2002, Blood 99: 1730-1740; O'Reilly et al., 2007, Immunol Res. 38:237-250; or Barker et al., 2010, Blood 116:5045-5049.
• the allogeneic T cells are enriched from peripheral blood lymphocytes separated from PBMCs of the donor of the allogeneic T cells. In a further specific embodiment, T cells are enriched from peripheral blood lymphocytes separated from PBMCs of the donor of the allogeneic T cells by depletion of adherent monocytes followed by depletion of natural killer cells. In various embodiments, the allogeneic T cells are
• cryopreserved for storage In a specific embodiment, wherein the allogeneic T cells are cryopreserved, the cryopreserved allogeneic T cells are thawed and expanded in vitro before sensitizing. In a specific embodiment, wherein the allogeneic T cells are cryopreserved, the cryopreserved allogeneic T cells are thawed and then sensitized, but not expanded in vitro before sensitizing, and then optionally expanded. In specific embodiments, the allogeneic T cells are cryopreserved after sensitizing (sensitizing produces the EBV-specific T cells). In a specific embodiment, wherein the allogeneic T cells are cryopreserved after sensitizing, the
• cryopreserved allogeneic T cells are thawed and expanded in vitro to produce the population of allogeneic T cells comprising EBV-specific T cells.
• the cryopreserved allogeneic T cells are thawed but not expanded in vitro to produce the population of allogeneic T cells comprising EBV-specific T cells.
• the allogeneic T cells are not
• the step of generating the population of allogeneic T cells in vitro further comprises, after sensitizing, cryopreserving the allogeneic T cells.
• the methods of treating an EBV-LPD as described herein further comprise, before the administering step, steps of thawing cryopreserved EBV- antigen sensitized allogeneic T cells, and expanding the allogeneic T cells in vitro, to produce the population of allogeneic T cells.
• the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells using EBV-transformed B cells (i.e., contacting allogeneic T cells with EBV-transformed B cells).
• EBV-transformed B cells i.e., contacting allogeneic T cells with EBV-transformed B cells.
• B cells transformed by EBV strain B95.8, for example, can be used for this purpose.
• the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells using dendritic cells (preferably, the dendritic cells are derived from the donor of allogeneic T cells).
• the step of sensitizing allogeneic T cells using dendritic cells comprises loading the dendritic cells with at least one immunogenic peptide derived from one or more EBV antigens.
• the step of sensitizing allogeneic T cells using dendritic cells comprises loading the dendritic cells with a pool of overlapping peptides derived from one or more EBV antigens.
• the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells using cytokine-activated monocytes (preferably, the cytokine-activated monocytes are derived from the donor of allogeneic T cells).
• the step of sensitizing allogeneic T cells using cytokine-activated monocytes comprises loading the cytokine-activated monocytes with at least one immunogenic peptide derived from one or more EBV antigens.
• the step of sensitizing allogeneic T cells using cytokine-activated monocytes comprises loading the cytokine-activated monocytes with a pool of overlapping peptides derived from one or more EBV antigens.
• the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells using peripheral blood mononuclear cells (preferably, the peripheral blood mononuclear cells are derived from the donor of allogeneic T cells).
• the step of sensitizing allogeneic T cells using peripheral blood mononuclear cells comprises loading the peripheral blood mononuclear cells with at least one immunogenic peptide derived from one or more EBV antigens.
• the step of sensitizing allogeneic T cells using peripheral blood mononuclear cells comprises loading the peripheral blood mononuclear cells with a pool of overlapping peptides derived from one or more EBV antigens.
• the step of generating the population of allogeneic T cells in vitro comprises sensitizing allogeneic T cells using artificial antigen-presenting cells
• the step of sensitizing allogeneic T cells using AAPCs comprises loading the AAPCs with at least one immunogenic peptide derived from one or more EBV antigens. In specific embodiments, the step of sensitizing allogeneic T cells using AAPCs comprises loading the AAPCs with a pool of overlapping peptides derived from one or more EBV antigens. In specific embodiments, the step of sensitizing allogeneic T cells using AAPCs comprises engineering the AAPCs to express at least one immunogenic EBV peptide or protein in the AAPCs.
• the pool of peptides is a pool of overlapping peptides spanning an antigen of EBV. In various embodiments, the pool of peptides is a pool of overlapping peptides spanning more than one antigen of EBV. In a specific embodiment, the pool of overlapping peptides is a pool of overlapping pentadecapeptides.
• the population of allogeneic T cells has been
• the methods of treating an EBV-LPD as described herein further comprise, before the administering step, a step of thawing a cryopreserved form of the population of allogeneic T cells.
• the population of allogeneic T cells is derived from a T cell line.
• the T cell line has been cryopreserved for storage before administering.
• the T cell line has not been cryopreserved for storage before administering.
• the T cell line has been expanded in vitro to derive the population of allogeneic T cells. In other embodiments, the T cell line has not been expanded in vitro to derive the population of allogeneic T cells.
• the T cell line can be sensitized to one or more EBV antigens (so as to produce EBV-specific T cells, for example, by a sensitizing step described above) before or after cryopreservation (if the T cell line has been cryopreserved), and before or after expanding in vitro (if the T cell line has been expanded in vitro).
• the methods of treating an EBV-LPD as described herein further comprise, before the administering step, a step of selecting the T cell line from a bank of a plurality of cryopreserved T cell lines (preferably each comprising EBV-specific T cells).
• unique identifier for each T cell line in the bank is associated with information as to which HLA allele(s) the respective T cell line is restricted, and optionally also information as to the HLA assignment of the respective T cell line.
• the methods of treating an EBV-LPD as described herein further comprise, before the administering step, a step of thawing a cryopreserved form of the T cell line.
• the methods of treating an EBV-LPD as described herein further comprises, before the administering step, a step of expanding the T cell line (for example, after thawing a cryopreserved form of the T cell line) in vitro.
• the T cell line and the plurality of cryopreserved T cell lines can be generated by any method known in the art, for example, as described in Koehne, et al., 2002, Blood 99: 1730-1740; O'Reilly et al., 2007, Immunol Res. 38:237-250; Barker et al., 2010, Blood 116:5045-5049, or as describe above for generating the population of allogeneic T cells in vitro.
• the population of allogeneic T cells comprising EBV-specific T cells that is administered to the human patient comprises CD8+ T cells, and in a specific embodiment also comprises CD4+ T cells.
• the EBV-specific T cells administered in accordance with the methods described herein recognize at least one antigen of EBV.
• the EBV-specific T cells administered in accordance with the methods described herein recognizes an EBV antigen that is EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, LMP1 or LMP2.
• the route of administration of the population of allogeneic T cells and the amount to be administered to the human patient can be determined based on the condition of the human patient and the knowledge of the physician. Generally, the administration is intravenous.
• the administering is by infusion of the population of allogeneic T cells.
• the infusion is bolus intravenous infusion.
• the administering comprises administering at least about 1 x 10 5 T cells of the population of allogeneic T cells per kg per dose per week to the human patient.
• the administering comprises administering about 1 x 10 6 to about 2 x 10 6 T cells of the population of allogeneic T cells per kg per dose per week to the human patient.
• the administering comprises administering about 1 x 10 6 T cells of the population of allogeneic T cells per kg per dose per week to the human patient.
• the administering comprises administering about 2 x 10 6 T cells of the population of allogeneic T cells per kg per dose per week to the human patient.
• the methods of treating an EBV-LPD as described herein comprise administering at least 2 doses of the population of allogeneic T cells to the human patient. In specific embodiments, the methods of treating an EBV-LPD as described herein comprise administering 2, 3, 4, 5, or 6 doses of the population of allogeneic T cells to the human patient.
• the methods of treating an EBV-LPD as described herein comprise administering a first cycle of one dose per week of the population of allogeneic T cells for 3 consecutive weeks followed by a washout period during which no dose of the population of allogeneic T cells is administered, followed by a second cycle of the one dose per week of the population of allogeneic T cells for 3 consecutive weeks.
• the methods of treating an EBV-LPD as described herein comprise administering at least two cycles of one dose per week of the population of allogeneic T cells for 3 consecutive weeks, each cycle separated by a washout period during which no dose of the population of allogeneic T cells is administered.
• the methods of treating an EBV-LPD as described herein comprise administering two, three, four, five, or six cycles of one dose per week of the population of allogeneic T cells for 3 consecutive weeks, each cycle separated by a washout period during which no dose of the population of allogeneic T cells is administered.
• the washout period is about three weeks.
• an additional cycle is administered only when the previous cycle has not exhibited toxicity (for example, no grade 3-5 serious adverse events, graded according to NCI CTCAE 4.0).
• a first dosage regimen described herein is carried out for a first period of time, followed by a second and different dosage regimen described herein that is carried out for a second period of time, wherein the first period of time and the second period of time are optionally separated by a washout period (for example, about three weeks).
• the second dosage regimen is carried out only when the first dosage regimen has not exhibited toxicity (for example, no grade 3-5 serious adverse events, graded according to NCI CTCAE 4.0).
• the methods of treating an EBV-LPD further comprise, after administering to the human patient the population of allogeneic T cells, administering to the human patient a second population of allogeneic T cells comprising EBV-specific T cells;
• the second population of allogeneic T cells is restricted by a different HLA allele shared with cells of the EBV-LPD.
• the second population of allogeneic T cells can be administered by any route and any dosage/administration regimen as described in Section 4.4.
• the methods of treating an EBV-LPD comprise administering a first cycle of one dose per week of the population of allogeneic T cells for 3 consecutive weeks followed by a washout period during which no dose of the population of allogeneic T cells is administered, followed by a second cycle of one dose per week of the second population of allogeneic T cells for 3 consecutive weeks.
• the washout period is about three weeks.
• the human patient has no response, an incomplete response, or a suboptimal response (i.e., the human patient may still have a substantial benefit from continuing treatment, but has reduced chances of optimal long-term outcomes) after administering the population of allogeneic T cells and prior to administering the second population of allogeneic T cells.
• two populations of allogeneic EBV-specific T cells that are each restricted by a different HLA allele shared with cells of the EBV-LPD are administered serially.
• three populations of allogeneic EBV-specific T cells that are each restricted by a different HLA allele shared with cells of the EBV-LPD are administered serially.
• four populations of allogeneic EBV-specific T cells that are each restricted by a different HLA allele shared with cells of the EBV-LPD are administered serially.
• more than four populations of allogeneic EBV-specific T cells that are each restricted by a different HLA allele shared with cells of the EBV-LPD are administered serially.
• the human patient can be anyone who has an EBV-LPD and who has failed combination chemotherapy to treat the EBV-LPD (and in some embodiments, also has failed therapy with an anti-CD20 monoclonal antibody) and/or radiation therapy (and in some embodiments, also has failed therapy with an anti-CD20 monoclonal antibody).
• LPDs are conditions in which lymphocytes are excessively proliferating, and can occur in immunocompromised patients.
• EBV-LPDs that can be treated by the methods described herein include, but are not limited to, B-cell hyperplasia, B-cell lymphoma (for example, diffuse large B-cell lymphoma), T-cell lymphoma, polymorphic or monomorphic EBV-LPD, EBV- positive Hodgkin's lymphoma, Burkitt lymphoma, autoimmune lymphoproliferative syndrome, and mixed PTLD (post-transplant lymphoproliferative disorder).
• B-cell hyperplasia B-cell lymphoma (for example, diffuse large B-cell lymphoma), T-cell lymphoma, polymorphic or monomorphic EBV-LPD, EBV- positive Hodgkin's lymphoma, Burkitt lymphoma, autoimmune lymphoproliferative syndrome, and mixed PTLD (post-transplant lymphoprolifer
• the EBV-LPD is an EBV-positive lymphoma (for example, and EBV-positive B-cell lymphoma).
• the EBV-LPD treated in accordance with a method described herein is present in the central nervous system of the human patient.
• the EBV- LPD treated in accordance with a method described herein is present in the brain of the human patient.
• the human patient has been immunocompromised.
• the human patient has been the recipient of a transplant.
• the human patient has been the recipient of a solid organ transplant from a transplant donor.
• the human patient has been the recipient of multiple organ transplants (for example, heart and lung transplants, or kidney and pancreas transplants).
• the solid organ transplant can be, but is not limited to, a kidney transplant, a liver transplant, a heart transplant, an intestinal transplant, a pancreas transplant, a lung transplant, or a
• the solid organ transplant is a kidney transplant. In another specific embodiment, the solid organ transplant is a liver transplant.
• the human patient has been the recipient of a hematopoietic stem cell transplant (HSCT) from a transplant donor.
• the HSCT can be a bone marrow transplant, a peripheral blood stem cell transplant, or a cord blood transplant.
• the population of allogeneic T cells is derived from a donor other than the transplant donor. In other specific embodiments, the population of allogeneic T cells is derived from the transplant donor. In various embodiments, the human patient has not been the recipient of a transplant.
• the human patient is a patient infected with HIV.
• the human patient has received immunosuppressant therapy (for example, after solid organ transplant).
• the dosage of the immunosuppressant given to the human patient has been reduced, and the human patient has failed the therapy for the EBV-LPD of reducing the immunosuppressant dosage.
• the human patient has a primary immunodeficiency (for example, a genetic disorder that has caused immunodeficiency).
• a primary immunodeficiency for example, a genetic disorder that has caused immunodeficiency.
• the human patient has not been immunocompromised.
• lymphoma was assessed for origin (SOT donor vs host).
• high resolution HLA testing of SOT donor tissue was performed for at least one allele with the goal of finding a line that was restricted by HLA alleles on both the host and the solid organ donor.
• T cell lines were selected from a bank of allogeneic T cell lines (each comprising
• EBV-specific T cells that shared at least 2/8 HLA alleles (A, B, C and DR) at high resolution with the patient and HLA restricted in recognition of EBV through an allele known to be expressed by the lymphoma or by alleles expressed by both the host and the solid organ donor tissue.
• EBV-LPDs present in the brain are especially difficult to treat by chemotherapies and radiation therapies, because many chemotherapeutic agents cannot cross the blood-brain barrier, and radiation therapies normally cause damages to the brain; however a partial remission was achieved with the patient with brain involvement.
• That first cycle of T cell therapy was graded NE (not evaluable) and he had a slight response at the end. After subsequent cycles he had near resolution while receiving EBV-specific T cells as the only therapy for the EBV-LPD.
• T cell treatments exhibited low toxicity.
• ANHL0131 doxorubicin, vincristine, prednisone, IT methotrexate
• vinblastine CCNU

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Epidemiology (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Virology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Immunology (AREA)
• Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Cell Biology (AREA)
• Hematology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Biomedical Technology (AREA)
• Developmental Biology & Embryology (AREA)
• Zoology (AREA)
• Molecular Biology (AREA)
• Dermatology (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (16)

Applications Claiming Priority (2)

Publications (1)

Family

ID=56027234

Family Applications (1)

Country Status (18)

Cited By (5)

Families Citing this family (3)

Family Cites Families (10)

• 2016
  • 2016-05-11 JP JP2017559029A patent/JP7284556B2/ja active Active
  • 2016-05-11 RU RU2017143151A patent/RU2720245C2/ru active
  • 2016-05-11 EP EP16724230.4A patent/EP3294304B1/en active Active
  • 2016-05-11 NZ NZ736675A patent/NZ736675A/en unknown
  • 2016-05-11 AR ARP160101364A patent/AR104598A1/es unknown
  • 2016-05-11 US US15/572,557 patent/US10568908B2/en active Active
  • 2016-05-11 KR KR1020177034692A patent/KR102666781B1/ko active Active
  • 2016-05-11 AU AU2016262484A patent/AU2016262484B2/en active Active
  • 2016-05-11 WO PCT/US2016/031784 patent/WO2016183153A1/en not_active Ceased
  • 2016-05-11 CA CA2984178A patent/CA2984178C/en active Active
  • 2016-05-11 BR BR112017024431-4A patent/BR112017024431B1/pt active IP Right Grant
  • 2016-05-11 MX MX2017014257A patent/MX386334B/es unknown
  • 2016-05-11 CN CN201680039509.4A patent/CN107835690A/zh active Pending
• 2017
  • 2017-10-27 ZA ZA2017/07335A patent/ZA201707335B/en unknown
  • 2017-11-02 PH PH12017501993A patent/PH12017501993A1/en unknown
  • 2017-11-09 IL IL255581A patent/IL255581B/en active IP Right Grant
  • 2017-11-10 CL CL2017002846A patent/CL2017002846A1/es unknown
• 2021
  • 2021-04-19 JP JP2021070234A patent/JP2021119154A/ja active Pending
• 2023
  • 2023-06-14 FR FR23C1025C patent/FR23C1025I2/fr active Active

Non-Patent Citations (38)

Also Published As

Similar Documents

Legal Events